AN2 Therapeutics, Inc.
NASDAQ:ANTX
1.25 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | AN2 Therapeutics, Inc. |
Symbool | ANTX |
Munteenheid | USD |
Prijs | 1.255 |
Beurswaarde | 37,498,007 |
Dividendpercentage | 0% |
52-weken bereik | 0.87 - 21.55 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Eric E. Easom |
Website | https://www.an2therapeutics.com |
An error occurred while fetching data.
Over AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)